为胎盘功能不全获得孤儿药资格认定:欧洲年发病率估算
本研究基于文献综述及已发表的欧盟与国家统计数据,估算胎盘功能不全(估测胎儿体重低于第10百分位且脐动脉多普勒血流异常)在欧盟人群中的年发病率,用于申请欧洲药品管理局(EMA)孤儿药资格认定。两项队列研究加权平均估计受累妊娠比例为3.17%(95%CI 2.93-3.43%),按2012年出生率并校正1/100的妊娠丢失率,年发病率估计为每1万欧盟人口3.33例(95%CI 3.07-3.60),低于EMA每1万人口5例的阈值。作者据此指出,针对胎盘功能不全的母体血管内皮生长因子基因治疗已于2015年获得EMA孤儿药资格。
要点
- 受累妊娠比例估计为3.17%(95%CI 2.93-3.43%),来自两项队列研究的加权平均。
- 按2012年出生率校正1/100妊娠丢失率,年发病率为每1万欧盟人口3.33例(95%CI 3.07-3.60)。
- 该估算值低于EMA孤儿药认定阈值每1万欧盟人口5例。
核心结论
- 胎盘功能不全(估测胎儿体重低于第10百分位且脐动脉多普勒血流异常)的年发病率估计为每1万欧盟人口3.33例(95%CI 3.07-3.60),低于EMA孤儿药认定阈值每1万欧盟人口5例。
- 针对胎盘功能不全的母体血管内皮生长因子基因治疗已于2015年获得EMA孤儿药资格。
- 作者认为其他潜在产科疗法的开发者应考虑申请孤儿药资格认定,因其可带来财务与监管方面的获益。
研究设计与样本
- 基于文献综述及已发表的欧盟与国家统计数据的发病率估算研究。
- 数据来源包括国家和国际指南、国际共识声明、队列研究、随机对照试验,以及出生率和死产率等国家与欧盟统计数据,并检索了罕见病数据库。
- 研究人群为欧盟人群,受累妊娠比例采用两项队列研究结果的加权平均估算。
主要发现
- 受累妊娠比例估计为3.17%(95%CI 2.93-3.43%),为两项队列研究结果的加权平均。
- 使用2012年出生率并校正1/100的妊娠丢失率后,估计年发病率为每1万欧盟人口3.33例(95%CI 3.07-3.60)。
- 该估计年发病率低于EMA孤儿药认定阈值每1万欧盟人口5例。
关键数值与推荐
- 胎盘功能不全定义为估测胎儿体重低于第10百分位且脐动脉多普勒血流异常。
- EMA孤儿药认定的发病阈值标准为每1万欧盟人口5例。
- 估计年发病率为每1万欧盟人口3.33例(95%CI 3.07-3.60),低于上述阈值。
临床怎么用
- 作者认为,其他潜在产科疗法的开发者应考虑申请孤儿药资格认定,因其可提供财务与监管方面的获益。
- 针对胎盘功能不全的母体血管内皮生长因子基因治疗已于2015年获得EMA孤儿药资格。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether a novel therapy for placental insufficiency could achieve orphan drug status by estimating the annual incidence of placental insufficiency, defined as an estimated fetal weight below the 10th centile in the presence of abnormal umbilical artery Doppler velocimetry, per 10 000 European Union (EU) population as part of an application for European Medicines Agency (EMA) orphan designation. DESIGN: Incidence estimation based on literature review and published national and EU statistics. SETTING AND POPULATION: European Union. METHODS: Data were drawn from published literature, including national and international guidelines, international consensus statements, cohort studies and randomised controlled trials, and published national and EU statistics, including birth rates and stillbirth rates. Rare disease databases were also searched. RESULTS: The proportion of affected pregnancies was estimated as 3.17% (95% CI 2.93-3.43%), using a weighted average of the results from two cohort studies. Using birth rates from 2012 and adjusting for a pregnancy loss rate of 1/100 gave an estimated annual incidence of 3.33 per 10 000 EU population (95% CI 3.07-3.60 per 10 000 EU population). This fell below the EMA threshold of 5 per 10 000 EU population. CONCLUSIONS: Maternal vascular endothelial growth factor gene therapy for placental insufficiency was granted EMA orphan status in 2015 after we demonstrated that it is a rare, life-threatening or chronically debilitating and currently untreatable disease. Developers of other potential obstetric therapies should consider applying for orphan designation, which provides financial and regulatory benefits. TWEETABLE ABSTRACT: Placental insufficiency meets the European Medicines Agency requirements for orphan disease designation.
引用
- Spencer R, Rossi C, Lees M, et al. Achieving orphan designation for placental insufficiency: annual incidence estimations in Europe. BJOG. 2019. PMID: 30576053. doi:10.1111/1471-0528.15590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。